Systematic analysis of time-dependent neural effects of soluble amyloid β oligomers in culture and in vivo: Prevention by scyllo-inositol

Neurobiology of Disease

Volumn 82, Issue , 2015, Pages 152-163

  Jin, Ming ^a   Selkoe, Dennis J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Alzheimer's disease; Microglia; Scyllo inositol; Soluble A oligomers; Synapses

Indexed keywords

AMYLOID BETA PROTEIN; CENTRAL NERVOUS SYSTEM AGENTS; OLIGOMER; SCYLLO INOSITOL; TAU PROTEIN; UNCLASSIFIED DRUG; AMPA RECEPTOR; GLUTAMATE RECEPTOR IONOTROPIC, AMPA 1; INOSITOL; SCYLLITOL;

ADULT; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; EMBRYO; FEMALE; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MICROGLIA; MOUSE; NERVE CELL CULTURE; NONHUMAN; PHENOTYPE; PRIMARY CELL CULTURE; PRIORITY JOURNAL; RAT; STEREOISOMERISM; ANIMAL; BRAIN; CELL CULTURE; DRUG EFFECTS; HIPPOCAMPUS; METABOLISM; NERVE CELL; PATHOLOGY; PHOSPHORYLATION; TIME FACTOR;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; CELLS, CULTURED; HIPPOCAMPUS; HUMANS; INOSITOL; MICE; NEURONS; PHOSPHORYLATION; RECEPTORS, AMPA; TAU PROTEINS; TIME FACTORS;

EID: 84934986062     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2015.05.020     Document Type: Article

References (25)

1. Arispe N., et al. Alzheimer disease amyloid β protein forms calcium channels in bilayer membranes: blockade by trimethamine and aluminum. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:567-571.
2. Benilova I., et al. The toxic Abeta oligomer and Alzheimer's disease: an emperor in need of clothes. Nat. Neurosci. 2012, 15:349-357.
3. Cirrito J.R., et al. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J. Neurosci. 2003, 23:8844-8853.
4. Esparza T.J., et al. Amyloid-beta oligomerization in Alzheimer dementia versus high-pathology controls. Ann. Neurol. 2013, 73:104-119.
5. 2+-permeable AMPA receptors at perisynaptic sites by GluR1-S845 phosphorylation. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:20033-20038.
6. Herrup K. Reimagining Alzheimer's disease - an age-based hypothesis. J. Neurosci. 2010, 30:16755-16762.
7. Jin M., et al. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:5819-5824.
8. Joachim C., et al. Tau epitopes are incorporated into a range of lesions in Alzheimer's disease. J. Neuropathol. Exp. Neurol. 1987, 46:611-622.
9. Lacor P.N., et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J. Neurosci. 2007, 27:796-807.
10. Li S., et al. Soluble oligomers of amyloid beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 2009, 62:788-801.
11. Li S., et al. Soluble Abeta oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J. Neurosci. 2011, 31:6627-6638.
12. Mandelkow E.M., Mandelkow E. Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb. Perspect. Med. 2012, 2:a006247.
13. McLaurin J., et al. Phosphatidylinositol and inositol involvement in Alzheimer amyloid-beta fibril growth and arrest. J. Mol. Biol. 1998, 278:183-194.
14. McLaurin J., et al. Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit Abeta-induced toxicity. J. Biol. Chem. 2000, 275:18495-18502.
15. McLaurin J., et al. Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat. Med. 2006, 12:801-808.
16. O'Malley T.T., et al. Abeta dimers differ from monomers in structural propensity, aggregation paths and population of synaptotoxic assemblies. Biochem. J. 2014, 461:413-426.
17. Pimplikar S.W., et al. Amyloid-independent mechanisms in Alzheimer's disease pathogenesis. J. Neurosci. 2010, 30:14946-14954.
18. Robakis N.K. Mechanisms of AD neurodegeneration may be independent of Abeta and its derivatives. Neurobiol. Aging 2011, 32:372-379.
19. Roche K.W., et al. Characterization of multiple phosphorylation sites on the AMPA receptor GluR1 subunit. Neuron 1996, 16:1179-1188.
20. Salloway S., et al. A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology 2011, 77:1253-1262.
21. Shankar G.M., et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 2008, 14:837-842.
22. Small S.A., Duff K. Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron 2008, 60:534-542.
23. Sutherland C., et al. Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling. Biochem. J. 1993, 296(Pt 1):15-19.
24. Townsend M., et al. Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. Ann. Neurol. 2006, 60:668-676.
25. Walsh D., et al. Naturally secreted oligomers of the Alzheimer amyloid? Protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416:535-539.